HomeAI · summaries
Storia in 6 fonti
ADA ‘26: Lilly’s dominance, Pfizer’s ‘foundational’ drug and Roche’s ‘me-too’ option
At a big meeting for weight loss drugs, Lilly’s “triple G” therapy set a new standard as lingering doubts surrounded other competing treatments.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
statnews.com
Lilly shares safety, tolerability data on its next-gen obesity drug
Eli Lilly presented new safety and tolerability data on retatrutide at the annual meeting of the American Diabetes Association on Saturday.
- ·
markets.businessinsider.com
Eli Lilly’s (LLY) New Drug Gives Investors a Wake-Up Call as Data Bolsters the Stock’s Growth Story
Eli Lilly and Company (LLY) gave investors another reason to watch its obesity pipeline after new late-stage data showed that its experimental d...
